GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (XSWX:SDZ) » Definitions » Ending Cash Position

Sandoz Group AG (XSWX:SDZ) Ending Cash Position : CHF959 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Ending Cash Position?

Sandoz Group AG's Ending Cash Position for the quarter that ended in Dec. 2023 was CHF959 Mil.

Sandoz Group AG's quarterly Ending Cash Position increased from . 20 (CHF0 Mil) to Dec. 2022 (CHF69 Mil) and increased from Dec. 2022 (CHF69 Mil) to Dec. 2023 (CHF959 Mil).

Sandoz Group AG's annual Ending Cash Position increased from . 20 (CHF0 Mil) to Dec. 2022 (CHF69 Mil) and increased from Dec. 2022 (CHF69 Mil) to Dec. 2023 (CHF959 Mil).

Sandoz Group AG Ending Cash Position Historical Data

The historical data trend for Sandoz Group AG's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Ending Cash Position Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Ending Cash Position
68.94 959.06

Sandoz Group AG Semi-Annual Data
Dec22 Dec23
Ending Cash Position 68.94 959.06

Sandoz Group AG Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sandoz Group AG's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=63.994+895.069
=959

Sandoz Group AG's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=63.994+895.069
=959

Sandoz Group AG Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (XSWX:SDZ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (XSWX:SDZ) » Definitions » Ending Cash Position
Comparable Companies
XSWX:SFZN XSWX:PPGN ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 HKSE:03692 NBIX NSE:DIVISLAB BOM:500124 VTRS SZSE:000963 XPAR:IPN SHSE:600085 XTAE:TEVA SHSE:600196
Traded in Other Exchanges
SDZXF:USA SDZNY:USA SDZz:UK D8Y0:Germany
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Website
https://www.sandoz.com
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (XSWX:SDZ) Headlines

No Headlines